November 2, 2009 - Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, is showcasing its growing suite of oncology treatment technologies here at the 51st American Society for Radiology and Oncology (ASTRO) Meeting, November 1-5.
Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent System is also FDA-cleared for the treatment of other cancers or conditions where radiation therapy is indicated, including IORT (intra-operative radiation therapy).
Xoft also announced that Axxent eBx Systems have been installed recently at several luminary accounts, including UCLA Medical Center, Memorial Sloan Kettering Cancer Center, and Beth Israel Medical Center. The systems are currently being used to clinically treat patients for breast, endometrial and skin cancer, and will also be used for clinical studies investigating additional IORT applications.
As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications. Designed to deliver non-isotopic therapy directly to cancer sites during or following surgical removal, the Axxent System utilizes a proprietary miniaturized X-ray source and robotic controller and can be used to deliver radiation in minimally shielded therapeutic settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery which minimizes patient anxiety.
For more information: www.xoftinc.com
July 11, 2024 
